OTHER FUNCTIONS R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPME

其他功能

• 批准号: 8557149
• 负责人: THOMAS ZUPANCIC
• 金额: $ 24.95万
• 依托单位: ENLYTON, LTD
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-14 至 2013-06-13
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8557149
• 关键词: Address; Adenocarcinoma; Affect; Antibodies; Antibody Affinity; Applied Research; Binding; Biodistribution; Blood Circulation; Cancer Detection; Cancer Patient; Colorectal; Development; Disease; Dose; Drug Kinetics; Emission-Computed Tomography; Esophageal; Excision; Hour; Image; Imaging technology; Immunoglobulin Fragments; Label; Lung; Malignant Neoplasms; Marketing; Medical; Methods; Modification; Monoclonal Antibodies; Operative Surgical Procedures; Outcome; Pancreas; Patients; Photons; Radioisotopes; Series; Stomach; Surgeon; TAG-72 Antigen; Testing; Time; Tissues; attenuation; base; cancer imaging; effective therapy; in vivo; research and development; single photon emission computed tomography; tumor

Surgical resection of malignant tumors is the single most effective therapy for cancer. Long-term patient outcomes are strongly determined by the extent to which the surgeon can completely remove all diseased tissues. Present cancer imaging and detection methods often fail to provide a clear picture of the extent of disease. SPECT (single photon emission computed tomography) is a sizeable market with a large installed base of scanners. SPECT has not adequately been supported for use in cancer imaging. Recent developments ¿ SPECT/CT fused imaging technology with attenuation correction ¿ alter this picture. Enlyton proposes to develop and test a series of tunable antibody targeting compounds for SPECT imaging of adenocarcinoma (e.g., colorectal, pancreatic, gastric, esophageal, lung) in cancer patients. It is an aim of this proposal to construct specific antibody targeting compositions that can rapidly accumulate in tumors while clearing from circulation quickly. It is a further aim to validate in vivo the efficacy of the preferred single chain antibody configuration, and optimize the time to SPECT/CT imaging. The modified tumor targeting agent will be labeled with an appropriate radioisotope (123I) to enable dosing and imaging within 24 hours using existing SPECT and SPECT/CT imaging platforms.

手术切除恶性肿瘤是治疗癌症长期患者最有效的方法。 结果很大程度上取决于外科医生可以完全切除所有的程度 目前的癌症成像和检测方法通常无法提供清晰的图像。 SPECT（单光子发射计算机断层扫描）是一个规模相当大的市场。 SPECT 的大型安装基础尚未得到充分支持用于癌症成像。 最新进展 ¿具有衰减校正功能的 SPECT/CT 融合成像技术 ¿改变这个 图片。 Enlyton 提议开发和测试一系列用于 SPECT 的可调谐抗体靶向化合物 癌症患者的腺癌（例如结直肠癌、胰腺癌、胃癌、食管癌、肺癌）的成像。 该提案的一个目的是构建特异性抗体靶向组合物，该组合物可以快速 在肿瘤中积累，同时从循环中快速清除，进一步的目标是在体内验证。 首选单链抗体配置的功效，并优化 SPECT/CT 时间 改良的肿瘤靶向剂将用适当的放射性同位素（123I）标记以进行成像。 使用现有的 SPECT 和 SPECT/CT 成像平台可在 24 小时内进行给药和成像。